BIVI vs. ENLV, AYTU, CLRB, PMVP, VSTM, CLSD, LFVN, PRPH, ETON, and TLSA
Should you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Enlivex Therapeutics (ENLV), Aytu BioPharma (AYTU), Cellectar Biosciences (CLRB), PMV Pharmaceuticals (PMVP), Verastem (VSTM), Clearside Biomedical (CLSD), LifeVantage (LFVN), ProPhase Labs (PRPH), Eton Pharmaceuticals (ETON), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical preparations" industry.
BioVie (NASDAQ:BIVI) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
Enlivex Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.
BioVie currently has a consensus price target of $8.00, indicating a potential upside of 1,656.31%. Enlivex Therapeutics has a consensus price target of $7.00, indicating a potential upside of 414.71%. Given BioVie's higher possible upside, analysts clearly believe BioVie is more favorable than Enlivex Therapeutics.
Enlivex Therapeutics' return on equity of -71.00% beat BioVie's return on equity.
Enlivex Therapeutics received 33 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 64.00% of users gave BioVie an outperform vote.
In the previous week, Enlivex Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 4 mentions for Enlivex Therapeutics and 3 mentions for BioVie. BioVie's average media sentiment score of 1.44 beat Enlivex Therapeutics' score of 0.95 indicating that BioVie is being referred to more favorably in the media.
BioVie has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.
4.6% of BioVie shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 4.8% of BioVie shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Enlivex Therapeutics beats BioVie on 9 of the 14 factors compared between the two stocks.
Get BioVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
